.webp "bioconjugates")
Bioconjugates, and specifically antibody-drug conjugates (ADCs), are shaping the future of targeted therapeutics, offering patients more precise and effective ways to treat complex diseases. By combining the specificity of monoclonal antibodies with the potency of highly active small-molecule payloads, these therapies represent one of the most sophisticated modalities in modern pharmaceutical development.
With a pioneering legacy as the world's first FDA-approved ADC CDMO and first commercial ADC manufacturer, Piramal Pharma Solutions brings unmatched proficiency to this landscape. For more than two decades, we've delivered a comprehensive range of services across the drug life cycle to help partners bring these next-generation therapies to patients in need.
Whether you require fully integrated bioconjugate development or tailored standalone services, our scientific depth, containment capabilities, and regulatory track record enable you to move from concept to commercialization with confidence.
For partners seeking a fully integrated path, our ADCelerate™ program brings these capabilities together as a complete, end-to-end solution — from early R&D through GMP production in as fast as 12 months, with guaranteed delivery at a fixed price. For those with more targeted needs, our services are also available as standalone offerings. Click here to learn more about the ADCelerate™ journey.
Our integrated global network is the foundation of our bioconjugate offering. With state-of-the-art facilities in Grangemouth, UK; Riverview, USA; Lexington, USA; Turbhe, India; and Hyderabad, India, we deliver fully integrated development and manufacturing services spanning R&D through clinical and commercial manufacturing. The strategic alignment of these sites enables seamless transfer of materials, processes, and analytical methods across the bioconjugate life cycle. This allows us to deliver comprehensive, flexible, and efficient solutions tailored to client's development stage and technical requirements.
As our dedicated Bioconjugate Development & Manufacturing facility, Grangemouth is critical to our leadership position in the field – providing a complete conjugation offering from mg scale Proof of Concept (POC) studies, process development, and scale-up through to clinical and commercial supply. Supported by recent expansions and an impeccable regulatory record, the site has enabled us to develop hundreds of unique ADCs, complete over a thousand ADC batches, and manufacture several commercial ADCs.
At the core of our global bioconjugate operations is The Science Collective, a distinguished group of subject matter experts who provide strategic scientific leadership across every stage of development and manufacturing.
Drawing on deep expertise across APIs, peptides, bioconjugates, formulations, vaccines, biologics, and integrated solutions, this elite group provides the cross-functional insights our clients need to navigate their technical challenges. With their support and scientific oversight, Piramal Pharma Solutions is uniquely positioned to help you advance your complex bioconjugate programs.
Global Technical Lead, Peptides
VP & Global Head of Bioconjugate and Large Molecule R&D
VP & Global API Technical Lead
Co-Founder & Chief Operating Officer of Yapan Bio, a Piramal Pharma Ltd. Associate Company
VP & Global Head of Formulations R&D
Director of Development, Lexington Sterile Injectables Facility
.png)
-1.png)
.png)
.jpg)
.png)
.webp)
.webp)
.webp)
